New breast cancer treatment gives hope to young women
Younger women with breast cancer have been given the hope of living longer after what is described as “one of the greatest advances in breast cancer research in recent decades”.

Adding ribociclib, a targeted drug that disrupts cancer cells, to standard hormone therapy was found to boost survival among premenopausal patients who have an advanced form of the disease.

The risk of death was cut by almost a third compared with those treated with hormone therapy alone, according to the study presented at the American Society of Clinical Oncology’s annual meeting in Chicago.

“This is indescribably good news for patients and their families,” said Lady Delyth Morgan, the chief executive at Breast Cancer Care and Breast Cancer Now.

The research, led by Dr. Sara Hurvitz of the University of California in Los Angeles, followed 672 pre-menopausal women under the age of 59 who had advanced hormone receptor-positive, HER2-negative breast cancer.

Read more:
Dr. K●●●●l P●●●●●t and 55 others like this17 shares